Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AXL | P30530 | 12/20 | 0.55 |
| ▸ | MET | P08581 | 11/20 | 0.55 |
| ▸ | KDR | P35968 | 4/20 | 0.55 |
| ▸ | MERTK | Q12866 | 5/20 | 0.53 |
| ▸ | FLT1 | P17948 | 4/20 | 0.47 |
| ▸ | AURKB | Q96GD4 | 4/20 | 0.47 |
| ▸ | RET | P07949 | 3/20 | 0.47 |
| ▸ | KIT | P10721 | 3/20 | 0.47 |
| ▸ | FLT3 | P36888 | 3/20 | 0.47 |
| ▸ | AURKA | O14965 | 2/20 | 0.47 |
| ▸ | RIPK2 | O43353 | 2/20 | 0.47 |
| ▸ | ABL1 | P00519 | 2/20 | 0.47 |
| ▸ | EGFR | P00533 | 2/20 | 0.47 |
| ▸ | ERBB2 | P04626 | 2/20 | 0.47 |
| ▸ | NTRK1 | P04629 | 2/20 | 0.47 |
| ▸ | LCK | P06239 | 2/20 | 0.47 |
| ▸ | LYN | P07948 | 2/20 | 0.47 |
| ▸ | HCK | P08631 | 2/20 | 0.47 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.47 |
| ▸ | BCR | P11274 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL372297 | 1.00 | AXL (0.55) | AXLMETKDRMERTKFLT1 | |
| SCHEMBL374207 | 0.97 | AXL (0.55) | AXLMETKDRMERTKFLT1 | |
| SCHEMBL31412944 | 0.94 | MET (0.62) | AXLMETKDRMERTKFLT1 | |
| SCHEMBL408158 | 0.94 | MET (0.62) | AXLMETKDRMERTKFLT1 | |
| SCHEMBL2151304 | 0.91 | MET (0.49) | AXLMETKDRMERTKFLT1 | |
| SCHEMBL31105630 | 0.91 | MET (0.67) | AXLMETKDRMERTKFLT1 | |
| SCHEMBL31412923 | 0.90 | MET (0.57) | AXLMETKDRMERTKFLT1 | |
| SCHEMBL28676846 | 0.89 | MET (0.57) | AXLMETKDRMERTKFLT1 | |
| SCHEMBL28676521 | 0.88 | AXL (0.49) | AXLMETKDRMERTKFLT1 | |
| SCHEMBL3699549 | 0.88 | MET (0.55) | AXLMETKDRMERTKFLT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4552695-A2 | TYROSINE KINASES INHIBITORS AND USES THEREOF | Great Novel Therapeutics Biotech & Medicals Corporation (TW) | 2025-05-14 | — | — | EP | disclosed |
| CN-119841776-A | Tyrosine kinase inhibitors and uses thereof | 华上生技医药股份有限公司 | 2025-04-18 | — | — | CN | disclosed |
| US-20250120967-A1 | TYROSINE KINASES INHIBITORS AND USES THEREOF | Great Novel Therapeutics Biotech & Medicals Corporation (TW) | 2025-04-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250120967-A1 | TYROSINE KINASES INHIBITORS AND USES THEREOF | LCK, LTK, HIF1AN | AXL 339/4885MET 592/4885KDR 112/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.